Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 27.04.2026 2 BMC Cancer 1 Br J Cancer 1 Cancer 1 Cancer Cell 6 Cancer Lett 1 Cancer Sci 1 Chest 1 Clin Cancer Res 2 Clin Lung Cancer 1 Eur J Cancer 1 Genes Chromosomes Cancer 2 Int J Cancer 5 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Oncol 1 J Thorac Oncol 1 Lung Cancer 1 Mol Cancer Ther 2 Oncogene 1 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. ZHANG Y, Li Z, Zeng A, Ma D, et al
   The influence of the administration sequence of neoadjuvant immunotherapy combined with chemotherapy on the postoperative pathological response of stage IIA-IIIB non-small cell lung cancer.
   BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-16028.
   PubMed        
   
   
2. MA HL, Zhao MD, Meng JM, Peng F, et al
   Sequential thoracic radiotherapy following immunotherapy in advanced non-small cell lung cancer: a real-world retrospective cohort study on efficacy and safety.
   BMC Cancer. 2026 Apr 20. doi: 10.1186/s12885-026-16035.
   PubMed        
   
   

   
   Br J Cancer

3. ZHAO K, Zhang J, Wang R, Wang B, et al
   STAT3 signaling mediates EGFR-TKI resistance in non-small cell lung cancer by regulating stemness markers and telomerase, reversed by icaritin.
   Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03433.
   PubMed         Abstract available
   
   

   
   Cancer

4. KIM TM, Williamson SK, Papadopoulos KP, Hamid O, et al
   Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
   Cancer. 2026;132:e70396.
   PubMed         Abstract available
   
   

   
   Cancer Cell

5. PLANCHARD D, Cozic N, Mosele MF, Corcos N, et al
   Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.
   Cancer Cell. 2026 Apr 17:S1535-6108(26)00171-6. doi: 10.1016/j.ccell.2026.
   PubMed         Abstract available
   
   

   
   Cancer Lett

6. LIU L, Wu Q, Fang S, Hu Z, et al
   Organoid-based modeling unveils Dnmt3a-driven epigenetic regulation of phenotypic plasticity in small cell lung cancer.
   Cancer Lett. 2026 Apr 16:218516. doi: 10.1016/j.canlet.2026.218516.
   PubMed         Abstract available
   
   
7. WEI T, Zhong G, Qian J, Wang J, et al
   Metabolic-epigenetic regulation of TRPM3 via H3K18 lactylation in dorsal root ganglia mediates bone cancer pain and its attenuation by microwave ablation.
   Cancer Lett. 2026;649:218505.
   PubMed         Abstract available
   
   
8. LEU JS, Deng H, Tran HN, Wei X, et al
   Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis.
   Cancer Lett. 2026;649:218491.
   PubMed         Abstract available
   
   
9. ZHOU Y, Zang R, Li Z, Zhang Z, et al
   Decoding the SHOX2 methylation-expression paradox in lung adenocarcinoma: Dual-regulatory methylation patterns drive oncogenic activation and prognostic relevance.
   Cancer Lett. 2026;648:218456.
   PubMed         Abstract available
   
   
10. HINZ TK, Le AT, Doan T, Ast A, et al
    Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.
    Cancer Lett. 2026;648:218467.
    PubMed         Abstract available
    
    
11. ZHANG Z, Yang X, Zheng R, Zang Y, et al
    Postoperative exosomal miR-1246 fuels hepatocellular carcinoma metastasis via BMP9-SMAD7 axis suppression.
    Cancer Lett. 2026;648:218469.
    PubMed         Abstract available
    
    

    
    Cancer Sci

12. GOTO Y, Nishio M, Ohashi K, Osoegawa A, et al
    Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.
    Cancer Sci. 2026 Apr 21. doi: 10.1111/cas.70375.
    PubMed         Abstract available
    
    

    
    Chest

13. ROBINSON SA, Shusterman S, Barker AM, Fix GM, et al
    Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth versus In-Person Discussions.
    Chest. 2026 Apr 21:S0012-3692(26)00455-1. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

14. LEE JB, Kim DK, Lee SH, Kim KH, et al
    A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naive Patients with Advanced Non-small Cell Lung Cancer.
    Clin Cancer Res. 2026 Apr 20. doi: 10.1158/1078-0432.CCR-25-4990.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. WILLIAMS C, Rogers J, Arasaratnam D, Pham T, et al
    Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort.
    Clin Lung Cancer. 2026 Mar 19:S1525-7304(26)00041.
    PubMed         Abstract available
    
    
16. NINIA JG, Verma N, Long JB, Laird JH Jr, et al
    Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State.
    Clin Lung Cancer. 2026;27:14-23.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

17. ARRIOLA E, Casarini I, Ozguroglu M, Huang M, et al
    Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
    Eur J Cancer. 2026;240:116744.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

18. BERMUDEZ LG, Forigua CB, Ayala-Roldan CM, Romero JM, et al
    Transcript-Specific DNA Methylation Alterations of the RASSF1 Locus in Cancer Cells.
    Genes Chromosomes Cancer. 2026;65:e70125.
    PubMed         Abstract available
    
    

    
    Int J Cancer

19. JIN H, Huang H, Wu Y, Zhang Y, et al
    Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.
    Int J Cancer. 2026;158:3187-3196.
    PubMed         Abstract available
    
    
20. NIEDERMAIER B, Bochtler T, Eichhorn F, Griffo R, et al
    Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
    Int J Cancer. 2026 Apr 19. doi: 10.1002/ijc.70508.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

21. CEDOZ E, Levy A, Martel-Lafay I, Bondiau PY, et al
    Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score Matching.
    Int J Radiat Oncol Biol Phys. 2026;125:112-122.
    PubMed         Abstract available
    
    
22. MAURY P, Sayous Y, Marnaoui R, Loiseau C, et al
    Stereotactic Ablative Radiotherapy (SABR) Quality and Survival of Patients with Head and Neck Cancer: a post-hoc analysis of the GORTEC 2014-04 "OMET" Randomised Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2025 Jul 24:S0360-3016(25)06019.
    PubMed         Abstract available
    
    
23. BAKER S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, et al
    The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:102-111.
    PubMed         Abstract available
    
    
24. CHETTY IJ, Zhong H
    Deformable Dose Mapping and Accumulation Techniques for Stereotactic Body Radiation Therapy (SBRT) of Lung Cancers.
    Int J Radiat Oncol Biol Phys. 2026;125:86-101.
    PubMed         Abstract available
    
    
25. KAO CF, Sheu RJ, Peir JJ, Wu YH, et al
    Development and Application of a Simplified Mathematical Model for The Estimation of Tumor Dose of Non-Small Cell Lung Cancer in BNCT.
    Int J Radiat Oncol Biol Phys. 2026 Apr 21:S0360-3016(26)00596.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

26. XUE W, Chen J
    Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.
    J Cancer Res Clin Oncol. 2026;152:92.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

27. PETERS S, Piha-Paul SA, Sehgal K, Calvo E, et al
    First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Apr 20:JCO2502016. doi: 10.1200/JCO-25-02016.
    PubMed         Abstract available
    
    
28. LI W, Zhang Y, Fan H, Yu Q, et al
    Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.
    J Clin Oncol. 2026 Apr 21:JCO2600434. doi: 10.1200/JCO-26-00434.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

29. STEWART CA, Ramkumar K, Wang R, Xi Y, et al
    YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.
    J Thorac Oncol. 2026 Apr 20:103730. doi: 10.1016/j.jtho.2026.103730.
    PubMed         Abstract available
    
    

    
    Lung Cancer

30. KUROSAKI T, Suzuki S, Watanabe Y, Kenmotsu H, et al
    Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
    Lung Cancer. 2026;216:109416.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

31. LIN YT, Liu YN, Hsu YC, Hsu YC, et al
    Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
    Mol Cancer Ther. 2026 Apr 20:OF1-OF10. doi: 10.1158/1535-7163.MCT-25-1214.
    PubMed         Abstract available
    
    

    
    Oncogene

32. WANG S, Tong X, Sun R, Xia X, et al
    STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4.
    Oncogene. 2026;45:1530-1543.
    PubMed         Abstract available
    
    
33. TANG J, Xu L, Gong Z, Chen L, et al
    USP7-mediated deubiquitination of the KEAP1-NRF2-HMOX1 axis enhances radioresistance in non-small cell lung cancer by suppressing ferroptosis.
    Oncogene. 2026 Apr 23. doi: 10.1038/s41388-026-03783.
    PubMed         Abstract available
    
    

    
    Oncol Rep

34. ZHOU Y, Ma J, Zhang J, He L, et al
    [Expression of Concern] Pifithrin?mu is efficacious against non?small cell lung cancer via inhibition of heat shock protein 70.
    Oncol Rep. 2026;55:118.
    PubMed         Abstract available
    
    

    
    PLoS One

35. KIM HB, Youm JY, Yang JM, Sim SB, et al
    High-intensity irreversible electroporation targeting intracellular structures enhance tumor ablation in lung cancer models.
    PLoS One. 2026;21:e0346472.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

36. ROBAY D, Ackermann O, Laborde L, Shi X, et al
    Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.
    Proc Natl Acad Sci U S A. 2026;123:e2508762123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum